⚠ Evidence warning: Clinical trials or other evidence do not support the claim that the earliest Milan gene therapy patients reached a complete cure with immune reconstitution lasting 20 or more years. This page keeps it as a report of what people, websites or other media say.

Severe Combined Immunodeficiency (SCID)

A T lymphocyte, the cell SCID infants lack
A T lymphocyte, the cell SCID infants lack
Pneumocystis, a fungus that strikes when T cells are missing
Pneumocystis, a fungus that strikes when T cells are missing

Table of Contents

  1. What Severe Combined Immunodeficiency Is
  2. Types of SCID: Genetics and Immune Phenotypes
  3. Signs and Symptoms: The First Year of Life
  4. Diagnosing SCID: Newborn Screening and Lab Tests
  5. Infections in SCID: Why Every Germ Is Dangerous
  6. Critical Rules: Vaccines and Blood Products
  7. Stem Cell Transplantation: The Path to a Cure
  8. Gene Therapy and Enzyme Replacement
  9. Newborn Screening (TREC) and Early Intervention
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Severe Combined Immunodeficiency Is

Severe Combined Immunodeficiency — known as SCID and sometimes called "bubble baby disease" — is the most serious of all primary immunodeficiencies. Unlike conditions where just one arm of the immune system is weakened, SCID destroys both major branches simultaneously: the T cells that direct and carry out immune attacks, and the B cells that manufacture antibodies. In most forms, natural killer (NK) cells — the immune system's rapid-response assassins — are also absent.

Think of your immune system as a military with two divisions working together: the T-cell division conducts targeted strikes against infected cells and commands the entire operation, and the B-cell division manufactures precision-guided missiles (antibodies) to neutralize threats. In SCID, neither division can report for duty. Without this combined defense, a baby is left almost completely naked against the microbial world — a world that, for healthy children, poses no serious danger at all.

Newborn screening of 3,030,083 babies in 11 U.S. programs found SCID in about 1 in 58,000 infants (95% confidence interval 1 in 46,000 to 1 in 80,000), higher than the 1 in 100,000 suggested by older clinical diagnoses. It is caused by mutations in any of more than 20 different genes, all of which ultimately result in the failure of T-cell development or function. The condition is uniformly fatal without treatment — almost no child with untreated SCID survives beyond the first two years of life, as relentless infections take their toll on a body with no immune defenses.

The good news is that SCID is curable. Hematopoietic stem cell transplantation (bone marrow transplant) can rebuild a functioning immune system from scratch, and when performed before a baby is three to four months old — ideally before any serious infection — survival rates exceed 90%. Universal newborn screening, now routine in all 50 U.S. states, makes this early intervention possible.

Back to Table of Contents

Types of SCID: Genetics and Immune Phenotypes

SCID is not one disease but a family of related disorders unified by the same devastating outcome: the failure of lymphocyte development. Each genetic form produces a characteristic immune phenotype — a specific pattern of which cell types are absent or present — which helps guide diagnosis and treatment planning.

X-Linked SCID (IL2RG mutation) — 19% of Screened Cases

The most common single gene in U.S. newborn screening, at 19% of 52 cases, against nearly half of cases in older cohorts from referral centers; the screening authors attribute the gap to better detection of autosomal recessive cases. The IL2RG gene on the X chromosome encodes the common gamma chain (γc), a signaling protein shared by six cytokine receptors: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. This shared chain is essential for the survival and proliferation of developing T cells and natural killer cells in the thymus and bone marrow. When it is absent, T cells and natural killer cells simply never develop. B cells are produced normally but are non-functional without T-cell help. The resulting immune phenotype is T− B+ NK−: no T cells, B cells present but useless, no natural killer cells. Because the gene is on the X chromosome, X-linked SCID almost exclusively affects boys — girls who carry a single defective copy are usually healthy.

JAK3 Deficiency (Autosomal Recessive)

JAK3 is the signaling enzyme that sits directly downstream of the common gamma chain. When it is defective, the same cytokine signaling failure occurs as in X-linked SCID, even though the receptor itself is intact. The phenotype is identical: T− B+ NK−. Unlike X-linked SCID, JAK3 deficiency affects boys and girls equally, since the gene is on chromosome 19.

ADA Deficiency (Autosomal Recessive) — 11% of Screened Cases

Adenosine deaminase (ADA) is an enzyme in the purine salvage pathway — a biochemical recycling system for cellular building blocks. When ADA is absent, toxic metabolites (primarily deoxyadenosine and its derivatives) accumulate inside lymphocytes to lethal levels. Every lymphocyte type is poisoned: T− B− NK−. ADA deficiency is a systemic metabolic disease, with noninfectious respiratory, neurological and biochemical complications besides the immune deficiency, and, crucially, one of the most treatable SCID forms — enzyme replacement therapy with a PEGylated enzyme (PEG-ADA; elapegademase replaced pegademase in 2018) can stabilize the disease, and gene therapy has achieved remarkable long-term results.

Interleukin-7 Receptor Deficiency (IL7R Mutation) — 12% of Screened Cases

Interleukin-7 is one of the cytokines that signals through the common gamma chain described above. When the interleukin-7 receptor’s own chain is defective, T cells fail to develop while B cells and natural killer cells are produced. Phenotype: T− B+ NK+. In U.S. newborn screening this accounted for 12% of the 52 cases; the six typical cases all had transplants and survived with donor cells engrafted. A founder mutation in Amish and Mennonite families is known.

RAG1 / RAG2 Mutations (Autosomal Recessive)

RAG1 and RAG2 are the molecular scissors that perform V(D)J recombination — the shuffling and cutting of gene segments that generates the enormous diversity of T-cell receptors and B-cell immunoglobulins. Without them, the immune system cannot build a repertoire of diverse lymphocytes. Natural killer cells, which do not use V(D)J recombination, develop normally. Phenotype: T− B− NK+.

Reticular Dysgenesis (AK2 Mutation)

The most severe SCID variant. Adenylate kinase 2 (AK2) is required for the survival of very early bone marrow precursors. When it fails, not only are all lymphocyte lineages absent, but neutrophils are also profoundly deficient. Patients have T− B− NK− plus severe neutropenia — a combination that leaves essentially no immune defense of any kind. Reticular dysgenesis requires urgent transplantation and carries the highest mortality if treatment is delayed.

Other Genetic Forms

Numerous other mutations cause SCID-spectrum disease. ZAP-70 deficiency selectively eliminates CD8+ cytotoxic T cells while sparing CD4+ helper T cells, resulting in a deceptively mild-appearing lymphocyte count that masks profound immune dysfunction. CD3 chain deficiencies (CD3δ, CD3ε, CD3ζ) impair T-cell receptor assembly. Artemis and DNA-PKcs mutations disrupt DNA repair during V(D)J recombination. CD45 deficiency blocks T-cell signaling. These rarer forms make up part of the remainder. In U.S. newborn screening, RAG1 accounted for 15% of the 52 cases, and in 15% no defect was found in any known SCID gene.

Back to Table of Contents

Signs and Symptoms: The First Year of Life

One of the most dangerous features of SCID is how normal newborns with the condition appear at first. In the first weeks to months of life, babies receive a temporary loan of their mother's antibodies — transferred across the placenta during pregnancy. This passive immunity masks the severity of SCID, giving parents and doctors a false sense of security before the catastrophe that follows.

The Initial Window: Weeks 0–4

Most babies with SCID appear healthy at birth and pass routine newborn checks. They feed normally, gain weight, and show no signs of illness. Maternal immunoglobulin G (IgG) antibodies circulating in the baby's blood provide some short-term protection against the pathogens the mother has previously encountered. Without newborn screening (TREC testing), SCID is completely invisible at this stage.

The Collapse: Months 4–7

As maternal antibodies degrade — with a half-life of approximately three weeks — protection evaporates. By four to seven months of age, most unscreened infants with SCID develop a characteristic cascade of problems:

The Absent Thymic Shadow

On a standard chest X-ray, the thymus gland — the organ where T cells mature — appears as a whitish shadow in the upper chest in healthy infants. In SCID, the thymus is tiny or absent because it has never received T-cell precursors to develop. The absence of a thymic shadow on a chest X-ray is a classic radiological clue to SCID diagnosis, though a normal shadow does not rule it out.

Back to Table of Contents

Diagnosing SCID: Newborn Screening and Lab Tests

The diagnosis of SCID requires a combination of newborn screening, clinical assessment, and targeted laboratory testing. The goal is always to identify the condition before serious infection occurs — because infection dramatically worsens transplant outcomes.

TREC Newborn Screening

Since 2010, the T-cell receptor excision circle (TREC) assay has been the cornerstone of SCID screening in the United States. TRECs are small circular DNA fragments produced as a byproduct when T cells rearrange their receptor genes in the thymus. Healthy newborns have high levels of TRECs in their blood spots because their thymus is actively producing new naive T cells. Infants with SCID have absent or extremely low TRECs because their thymus produces no T cells at all. The test is performed on the same dried blood spot card used for all newborn screening, requiring no extra blood draw. A positive (low TREC) result triggers immediate follow-up testing.

Complete Blood Count with Differential

The most important initial laboratory test. In SCID, the absolute lymphocyte count (ALC) is profoundly reduced — typically below 3,000 cells per microliter in an infant (normal values for infants are above 4,000). An ALC below 2,000 in a newborn is highly suspicious for SCID. The differential count also reveals whether specific populations are absent or reduced.

Flow Cytometry (Lymphocyte Immunophenotyping)

This test counts each lymphocyte subtype with precision by labeling cells with fluorescent antibodies that recognize surface markers: CD3 (T cells), CD4 (helper T cells), CD8 (cytotoxic T cells), CD19/CD20 (B cells), CD16/CD56 (natural killer cells). Flow cytometry determines the SCID phenotype — T− B+ NK−, T− B− NK+, or T− B− NK− — and guides genetic testing toward the most likely mutation.

Mitogen Stimulation (PHA Test)

Phytohemagglutinin (PHA) is a plant-derived compound that stimulates T cells to proliferate. In a healthy person, T cells respond robustly. In SCID, T-cell responses to PHA are absent or severely blunted. This functional test is a critical complement to cell counts because some variants of SCID can have residual T cells that are present in low numbers but completely non-functional.

Serum Immunoglobulins

Immunoglobulin G, immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are measured. Maternal immunoglobulin G obscures true immunoglobulin production for the first six months of life, making this test less reliable in young infants. Immunoglobulin A and immunoglobulin M, which are not transferred from mother to baby, are often absent or very low from birth in SCID, and their absence is a meaningful signal.

Genetic Testing

Once the clinical diagnosis is established, targeted gene sequencing confirms the specific mutation. Next-generation sequencing panels covering all known SCID genes have largely replaced single-gene testing. Genetic diagnosis is important for determining transplant conditioning requirements, identifying other at-risk family members, and enabling preimplantation genetic diagnosis in future pregnancies.

Back to Table of Contents

Infections in SCID: Why Every Germ Is Dangerous

To understand the danger of SCID, it helps to recognize that the micro-organisms threatening SCID patients are the same ones that surround all of us every day — in the air, on surfaces, in food, and even inside our own bodies. For healthy people these organisms pose no serious risk. For a child with SCID, each one is potentially lethal.

Pneumocystis jirovecii Pneumonia (PCP)

Pneumocystis jirovecii is a fungus that lives harmlessly in the lungs of virtually every healthy person without causing any symptoms. In SCID, it proliferates unchecked and causes a severe pneumonia characterized by progressive oxygen failure, bilateral "ground-glass" infiltrates on imaging, and, without treatment, death. PCP is often the presenting illness that first brings a SCID infant to medical attention — and its appearance in a very young infant is itself a red flag for underlying immunodeficiency. Prophylactic trimethoprim-sulfamethoxazole is the standard prevention for SCID patients, started as soon as the diagnosis is suspected.

Cytomegalovirus (CMV)

Cytomegalovirus infects more than half the adult population worldwide and causes a mild flu-like illness in most people. In SCID, CMV causes devastating pneumonitis, hepatitis, encephalitis, and retinitis. Cytomegalovirus-seronegative blood products and irradiation of all blood products are mandatory in SCID to prevent cytomegalovirus transmission through transfusion.

Respiratory Viruses

Viruses that cause a few days of sniffles in healthy children — respiratory syncytial virus (RSV), parainfluenza, adenovirus, and human metapneumovirus — cause progressive, often fatal, pneumonias in SCID patients. There are no effective antiviral treatments for most of these organisms, making prevention through strict infection control the only meaningful strategy.

Rotavirus

In healthy infants, rotavirus infection causes diarrhea for a few days. In SCID, rotavirus cannot be cleared. It replicates in the intestinal lining without restraint, causing chronic, voluminous diarrhea that leads to severe malnutrition, electrolyte crises, and death. The oral rotavirus vaccine — which is a live vaccine — lists SCID as a contraindication on its label, which also reports gastroenteritis in vaccinated infants with SCID (see Vaccine Rules section).

Candida and Other Fungi

Fungi that normally colonize skin and mucous membranes without causing harm become systemic invaders in SCID. Candida infections progress from thrush to esophagitis to bloodstream infection (candidemia) and involve organs including the liver, spleen, and kidneys. Aspergillus spores — inhaled constantly from the environment — cause invasive pulmonary aspergillosis that is very difficult to treat once established.

Maternal T-Cell Engraftment

During pregnancy, small numbers of maternal T cells naturally cross the placenta and enter fetal circulation. In a healthy fetus, these foreign cells are eliminated by the infant's own immune system within days of birth. In SCID, where the infant has no functional immune defenses, these maternal T cells survive and expand. Recognizing the baby's tissues as foreign, they mount an immune attack — a form of graft-versus-host disease (GVHD). Clinically, this presents as an erythrodermatous (red, scaly, widespread) rash, elevated liver enzymes, and diarrhea in the first weeks of life. This finding confirms the diagnosis of SCID and underscores the urgency of treatment.

Back to Table of Contents

Critical Rules: Vaccines and Blood Products

In immunodeficiency medicine, the vaccine and transfusion rules for SCID patients are a matter of life and death, and they are taught to the healthcare providers and family members of SCID patients.

Live Vaccines Are Absolutely Contraindicated

A live vaccine contains weakened (attenuated) but replicating organisms. In an immunocompetent person, these organisms cause a brief, controlled, subclinical infection that teaches the immune system to recognize the pathogen. In a SCID patient, there is no immune system to control the infection. The attenuated organism simply replicates without restraint — causing the very disease the vaccine was meant to prevent, often with catastrophic results.

Vaccine labels and immunization guidance list SCID or severe immunodeficiency as a contraindication to the following vaccines, for a child with known or suspected SCID:

Guidance for household contacts of a SCID patient excludes oral polio vaccine (if used internationally) and lists inactivated influenza vaccine rather than LAIV. After MMR vaccination, household contacts do not shed vaccine strain to vulnerable patients, so MMR for contacts is generally safe and protective.

Blood Product Rules

All blood product transfusions (red blood cells, platelets, granulocytes, fresh frozen plasma) for SCID patients are:

Back to Table of Contents

Stem Cell Transplantation: The Path to a Cure

Hematopoietic stem cell transplantation (HSCT) — commonly called a bone marrow transplant — is the definitive cure for SCID. The goal is to replace the patient's defective immune system with a healthy one from a donor. If performed in the first months of life, before serious infection takes hold, more than 90% of infants with SCID survive to lead normal lives.

Why Early Transplant Matters So Profoundly

The timing of transplantation is the single most important predictor of outcome. Landmark studies from the Primary Immune Deficiency Treatment Consortium (PIDTC) analyzed transplantation outcomes for over 200 SCID patients over a decade and found a stark difference: infants transplanted before three to four months of age, without prior serious infection, had survival rates exceeding 90%. Infants transplanted after a serious infection — particularly pneumonia or viral infections — had survival rates dropping to 50–70%. Infection damages the lungs, liver, and other organs that the immune system needs to recover from transplantation. Every week of delay carries real risk.

Donor Selection

The best outcome comes from a matched sibling donor — a healthy brother or sister with compatible human leukocyte antigen (HLA) tissue type. Unfortunately, fewer than 25% of patients have a matched sibling available. Alternatives include:

Conditioning Regimen

Before transplantation, some patients receive a conditioning regimen — chemotherapy, sometimes with radiation — to prepare the bone marrow to accept the donor cells. Whether conditioning is needed depends on the SCID phenotype:

After Transplantation

Immune reconstitution takes time. T cells are the first to appear, typically three to six months after transplantation as donor stem cells colonize the thymus and generate new T-cell clones. B-cell recovery and the ability to produce antibodies independently (without intravenous immunoglobulin supplementation) may take one to two years or longer, and some patients require long-term immunoglobulin replacement. Regular monitoring of immune cell counts, vaccine titers, and organ function is part of long-term follow-up care.

Back to Table of Contents

Gene Therapy and Enzyme Replacement

For certain forms of SCID, gene therapy offers an alternative to allogeneic transplantation — correcting the patient's own stem cells rather than replacing them with a donor's. This approach eliminates the risks of graft-versus-host disease and graft rejection, which are the two leading complications of transplantation from a non-perfect donor match.

Gene Therapy for ADA-SCID

An autologous CD34+ cell gene therapy using a gamma-retroviral vector was approved by the European Medicines Agency in 2016, becoming the first marketed gene therapy for a primary immunodeficiency. The patient's own bone marrow stem cells are collected, the ADA gene is inserted using a modified retrovirus as a delivery vehicle, and the corrected cells are returned to the patient. Accounts of the original patients from San Raffaele Hospital in Milan describe durable immune reconstitution at 20+ years, with some patients achieving complete cure. The largest long-term report (2024, 43 patients) found all alive at a median follow-up of 5.0 years overall and 15.4 years in the clinical development group, with 88% free at 2 years of long-term enzyme replacement or a donor transplant. One patient developed a T-cell leukemia related to treatment 4.7 years after gene therapy and is in remission. A newer lentiviral vector approach (EFS-ADA) is in advanced clinical trials and appears to offer improved safety and efficacy, with a more favorable insertion site profile. In 50 patients treated in the U.S. and U.K. with lentiviral gene therapy, all were alive at 24 and 36 months, event-free survival was 95–97%, and no leukoproliferative complications or graft-versus-host disease occurred.

Gene Therapy for X-Linked SCID

Early gamma-retroviral gene therapy trials for X-SCID achieved T-cell reconstitution in the majority of patients but were complicated by insertional mutagenesis — the retrovirus inserted near proto-oncogenes, causing T-cell leukemia in 5 of 20 patients across the Paris and London trials. This outcome led to a decade-long redesign effort. Newer lentiviral vectors, which have a safer integration profile, are currently in Phase I/II trials and have demonstrated T-cell, B-cell, and natural killer-cell reconstitution without evidence of insertional oncogenesis in early follow-up — a major advance. In eight infants given a lentiviral vector after low-dose busulfan and followed for a median of 16.4 months, T cells and natural killer cells normalized in seven by 3 to 4 months, four stopped immune globulin infusions, and no clonal dominance appeared in the seven analyzed.

Gene Therapy for Artemis-Deficient SCID

Artemis-deficient SCID responds poorly to donor transplantation. Ten infants received a lentiviral gene therapy and were followed for a median of 31.2 months. Five of the 6 followed for at least 24 months rebuilt T cells, four could stop antibody infusions, and four had autoimmune hemolytic anemia 4 to 11 months after infusion that resolved once T-cell immunity returned. All ten were healthy at the time of the report.

Gene Editing

CRISPR-based approaches are in preclinical and early clinical development for several SCID forms. Gene editing corrects the mutation at its precise location in the genome rather than inserting an extra copy of the gene, theoretically eliminating the risk of insertional mutagenesis entirely. Early results are promising, but clinical validation is still in progress.

Enzyme Replacement for ADA-SCID: Elapegademase (PEG-ADA)

Before gene therapy was available, and still used today as a bridge to transplantation or gene therapy, enzyme replacement provides intramuscular injections of the missing ADA enzyme attached to polyethylene glycol (PEG) molecules that extend its half-life in circulation. The original product, pegademase bovine, was replaced in 2018 by elapegademase, a recombinant PEGylated enzyme (FDA label: intramuscular use, initial U.S. approval 2018). PEG-ADA does not cure ADA-SCID — it does not correct the underlying genetic defect and immune reconstitution is partial — but it reduces toxic metabolite levels, stabilizes immune function, and keeps the patient alive and infection-free while awaiting definitive therapy. It has been used successfully as life-long therapy for patients who are not transplant candidates, though costs are extremely high (over $200,000 per year in the U.S.).

The 2019 expert consensus describes this sequence of care: all patients start on enzyme replacement, then have definitive treatment by either of two equal first-line options, a transplant from an HLA-matched sibling or family donor, or gene therapy using the child’s own stem cells. A 2025 registry of 32 patients on elapegademase for up to 4 years reported no new safety concerns; 66.7% of those switching from pegademase held satisfactory enzyme and metabolite levels, and variability was seen on all measures.

Back to Table of Contents

Newborn Screening (TREC) and Early Intervention

The introduction of TREC (T-cell receptor excision circle) newborn screening is one of the most important advances in the history of primary immunodeficiency care. Before widespread screening, the average age of SCID diagnosis was four to seven months — after significant infection had already occurred. Today, most U.S. infants with SCID are identified within the first week of life, before any symptoms appear.

How TREC Testing Works

When T cells mature in the thymus, they rearrange the DNA segments that encode their T-cell receptors — a process of molecular reshuffling that generates the extraordinary diversity needed to recognize the millions of different pathogens the immune system will encounter over a lifetime. As part of this recombination, small circular loops of DNA are cut out and discarded. These loops are TRECs — T-cell receptor excision circles. They are stable (they do not replicate), so they accumulate only in newly produced, naive T cells. Measuring TREC levels in a dried blood spot from the newborn heel stick gives a precise, quantitative readout of how many new T cells the thymus is exporting into the bloodstream.

A healthy newborn generates thousands of new T cells per day, resulting in high TREC levels. A newborn with SCID generates essentially none, resulting in absent or near-absent TRECs. The assay is highly sensitive for detecting all forms of SCID (including T− B+ NK−, T− B− NK+, and T− B− NK−) because all forms share the critical feature of absent naive T-cell production.

Screening Rollout and Coverage

TREC newborn screening began in Wisconsin in 2008, and SCID was added to the U.S. national recommended uniform screening panel in 2010. By 2018, all 50 U.S. states had incorporated TREC testing into their universal newborn screening panels. The test has also been adopted in many European countries, Taiwan, Israel, and New Zealand. Globally, neonatal TREC screening has transformed SCID from a disease of late diagnosis and poor outcomes to one where early identification and curative transplantation before infection is now the standard.

TREC-Positive Results and Follow-Up

A low TREC result triggers urgent follow-up, typically within 24–48 hours. Important: a low TREC is not always SCID. Prematurity (especially before 32 weeks), DiGeorge syndrome (22q11 deletion), and other conditions can lower TRECs without causing complete SCID. The differential diagnosis workup includes a complete blood count with lymphocyte differential, flow cytometry for T/B/natural killer cell counts, and chest X-ray for thymic shadow. In truly SCID-suspicious cases, the infant is referred immediately to a pediatric immunology center, placed in protective isolation, and evaluated for transplantation.

The Impact of Early Intervention

The difference between SCID diagnosed by newborn screening versus diagnosed after clinical presentation is stark. A landmark 2014 study in the New England Journal of Medicine analyzing PIDTC registry data (a retrospective study of 240 infants at 25 centers) found high survival regardless of donor type in infants transplanted at 3.5 months of age or younger (94%) and in older infants without prior infection (90%) or with infection that had resolved (82%), compared with significantly lower survival in infants with active infection at transplantation. Every day of unrecognized SCID is a day of accumulating immune damage. Newborn screening has effectively turned SCID from a near-universal death sentence into a condition where the majority of children grow up with fully functional immune systems.

Survival Figures From Screening Programs

Across 11 U.S. screening programs (3,030,083 newborns, 52 cases), survival through diagnosis and immune reconstitution was 87%, and 92% among infants who received a transplant, enzyme replacement or gene therapy. The largest study so far followed 902 children over 36 years: 5-year survival sat at 72–73% for 28 years, then rose to 87% in 2010–18. Children found by newborn screening since 2010 reached 92.5%, against 79.9% for those found through illness and 85.4% through family history. Active infection (hazard ratio 2.41), transplant at 3.5 months or older (hazard ratio 2.12) and being Black or African American (hazard ratio 2.33) each went with lower survival.

Back to Table of Contents

Key Research Papers

  1. Bonilla FA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205. — PubMed PMID: 26371839
  2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655. — PubMed PMID: 15032591
  3. Pai SY et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434-446. — PubMed PMID: 25075835
  4. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672. — PubMed PMID: 10784449
  5. Kohn DB et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019. — PubMed PMID: 30194989
  6. Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci. 2012;69(1):17-27. — PubMed PMID: 21984609
  7. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738. — PubMed PMID: 25138334
  8. Cicalese MP et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128(1):45-54. — PubMed PMID: 27129325
  9. Dvorak CC et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013;33(7):1156-1164. — PubMed PMID: 23818196
  10. Gaspar HB et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011. — PubMed PMID: 21865537
  11. Punwani D et al. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency. Hum Gene Ther. 2017;28(1):112-124. — PubMed PMID: 27611239
  12. Thakar MS, Logan BR, Puck JM, et al. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Lancet. 2023;402(10396):129-140. — PubMed PMID: 37352885
  13. Migliavacca M, Barzaghi F, Fossati C, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med. 2024;30(2):488-497. — PubMed PMID: 38355973
  14. Kohn DB, Booth C, Shaw KL, et al. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med. 2021;384(21):2002-2013. — PubMed PMID: 33974366
  15. Mamcarz E, Zhou S, Lockey T, et al. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019;380(16):1525-1534. — PubMed PMID: 30995372
  16. Cowan MJ, Yu J, Facchino J, et al. Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022;387(25):2344-2355. — PubMed PMID: 36546626
  17. Dorsey MJ, Butte MJ, Lieberman JA, et al. Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy. J Clin Immunol. 2025;45(1):84. — PubMed PMID: 40140214

Back to Table of Contents

Connections

Back to Table of Contents